Baruch, A., Luca, D., Kahn, R. S., Cowan, K. J., Leabman, M., Budha, N. R., . . . Tingley, W. G. (2017). A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. Clin Cardiol.
Čikaški stil citiranjaBaruch, Amos, et al. "A Phase 1 Study to Evaluate the Safety and LDL Cholesterol–lowering Effects of RG7652, a Fully Human Monoclonal Antibody against Proprotein Convertase Subtilisin/kexin Type 9." Clin Cardiol 2017.
MLA način citiranjaBaruch, Amos, et al. "A Phase 1 Study to Evaluate the Safety and LDL Cholesterol–lowering Effects of RG7652, a Fully Human Monoclonal Antibody against Proprotein Convertase Subtilisin/kexin Type 9." Clin Cardiol 2017.